首页 | 本学科首页   官方微博 | 高级检索  
检索        

利福霉素钠注射液联合利奈唑胺注射液对重症革兰阳性球菌感染患者炎症反应、血清降钙素原水平及不良反应的影响
引用本文:陈培莉,杨林,张辉,刘慧丽,马统帅.利福霉素钠注射液联合利奈唑胺注射液对重症革兰阳性球菌感染患者炎症反应、血清降钙素原水平及不良反应的影响[J].中国医院用药评价与分析,2020(4):425-427,431.
作者姓名:陈培莉  杨林  张辉  刘慧丽  马统帅
作者单位:商丘市第一人民医院重症监护室;商丘市第一人民医院儿科
基金项目:河南省医学科技攻关计划项目(No.2018020946)。
摘    要:目的:探讨利福霉素钠注射液联合利奈唑胺注射液对重症革兰阳性球菌感染患者炎症反应、血清降钙素原(PCT)水平及不良反应的影响。方法:选取2018年5月至2019年9月商丘市第一人民医院收治的重症革兰阳性球菌感染患者60例作为研究对象,按照随机数字表法分为研究组和对照组,每组30例。对照组患者给予利奈唑胺注射液治疗,研究组患者在对照组的基础上给予利福霉素钠注射液治疗。比较两组患者的临床疗效、炎症指标白细胞计数(WBC)、超敏C反应蛋白(hs-CRP)、白细胞介素1β(IL-1β)及白细胞介素10(IL-10)]水平、血清PCT水平及不良反应发生情况的差异。结果:研究组患者的总有效率明显高于对照组90.00%(27/30)vs.66.67%(20/30)],差异有统计学意义(P<0.05)。治疗后,两组患者血清WBC、CRP及IL-1β水平均较治疗前明显降低,血清IL-10水平较治疗前明显升高;且研究组患者血清WBC、CRP及IL-1β水平明显低于对照组,血清IL-10水平明显高于对照组,上述差异均有统计学意义(P<0.05)。治疗后,两组患者血清PCT水平均较治疗前明显降低,且研究组患者明显低于对照组,差异均有统计学意义(P<0.05)。研究组、对照组患者的不良反应发生率分别为23.33%(7/30)、26.67%(8/30),差异无统计学意义(P>0.05)。结论:利福霉素钠注射液联合利奈唑胺注射液治疗重症革兰阳性球菌感染的临床效果显著,能够有效降低患者血清PCT水平,改善炎症反应,缓解感染症状,具有一定的临床应用价值。

关 键 词:利奈唑胺  利福霉素钠  重症革兰阳性球菌感染  疗效  不良反应

Effects of Rifamycin Sodium Injection Combined with Linezolid Injection on Inflammatory Response,Serum Procalcitonin and Adverse Drug Reactions in Patients with Severe Gram-Positive Coccus Infection
CHEN Peili,YANG Lin,ZHANG Hui,LIU Huili,MA Tongshuai.Effects of Rifamycin Sodium Injection Combined with Linezolid Injection on Inflammatory Response,Serum Procalcitonin and Adverse Drug Reactions in Patients with Severe Gram-Positive Coccus Infection[J].Evaluation and Analysis of Drug-Use in Hospital of China,2020(4):425-427,431.
Authors:CHEN Peili  YANG Lin  ZHANG Hui  LIU Huili  MA Tongshuai
Institution:(Intensive Care Unit, Shangqiu First People’s Hospital, Henan Shangqiu 476000, China;Dept. of Pediatrics, Shangqiu First People’s Hospital, Henan Shangqiu 476000, China)
Abstract:OBJECTIVE:To probe into the effects of rifamycin sodium injection combined with linezolid injection on inflammatory response,serum procalcitonin(PCT)and adverse drug reactions in patients with severe gram-positive coccus infection.METHODS:Totally 60 patients with severe gram-positive coccus infection admitted into Shangqiu First People’s Hospital from May 2018 to Sept.2019 were extracted to be divided into the study group and the control group via the random number table,with 30 cases in each group.The control group was treated with linezolid injection,while the study group additionally received rifamycin sodium injection based on the control group.Differences of clinical efficacy,levels of inflammatory indexeswhite blood cell count(WBC),high-sensitivity C-reactive protein(hs-CRP),interleukin 1β(IL-1β)and interleukin 10(IL-10)],levels of serum PCT and adverse drug reactions of two groups were compared.RESULTS:The total effective rate in the study group was significantly higher than that in the control group90.00%(27/30)vs.66.67%(20/30)],and the difference was statistically significant(P<0.05).After treatment,the levels of serum WBC,CRP and IL-1βin two groups were significantly lower than those before treatment,and the levels of serum IL-10 were significantly higher than those before treatment;the levels of WBC,CRP and IL-1βin the study group were significantly lower than those in the control group,and the levels of IL-10 were significantly higher than those in the control group,differences were statistically significant(P<0.05).After treatment,the levels of serum PCT of two groups was significantly lower than those before treatment,and the study group was significantly lower than the control group,with statistically significant differences(P<0.05).The incidence of adverse drug reactions in the study group and the control group were 23.33%(7/30)and 26.67%(8/30),respectively,with no statistically significant difference(P>0.05).CONCLUSIONS:The clinical efficacy of rifamycin sodium injection combined with linezolid injection is remarkable,which can significantly reduce the levels of serum PCT,improve the inflammatory response of patients,relief the infection symptoms and has certain clinical application value.
Keywords:Linezolid  Rifamycin sodium  Severe gram-positive coccus infection  Efficacy  Adverse drug reactions
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号